News
Zacks Investment Research on MSN8d
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...
Regeneron (REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read more here.
Hosted on MSN1mon
Regeneron To Buy Licensing Rights For China-Developed ... - MSN
Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with China’s Hansoh Pharmaceuticals Group Company to acquire exclusive clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback